FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387310037> ?p ?o ?g. }

• W4387310037 endingPage "S73" @default.
• W4387310037 startingPage "S72" @default.
• W4387310037 abstract "The increasing number of gene therapy studies and exclusion of candidates from clinical trials highlights the potential importance of pre-existing antibodies targeting viral capsid. Viral antibodies block transduction and preclude expression of the transferred gene. Provoked immune response could also be a threat to safety. Testing patients for pre-existing antibodies, either neutralizing (Nabs) or total/binding (TAbs/BAbs), prior to gene transfer is a critical step in the initiation of a clinical trial. Previous studies assessed the seroprevalence of antibodies against different AAV subtypes in the general population and in patients receiving gene transfer. Our gene therapy studies for muscular dystrophy (DMD, LGMD) have currently shown promise for efficacy and safety, but we don't know if vector shedding post gene delivery affects the antibodies titer in family members of trial participants. This is particularly relevant for siblings who might become possible next gene therapy candidates. This pilot study included 115 subjects divided in three separate cohorts. Group 1 consisted of hospital personnel without known prior work exposure to rAAVrh74 (control group, 23 subjects). Group 2 were hospital-based personnel with known work exposure to rAAVrh74 (through pre-clinical and clinical studies, or direct contact with patient's specimen, 35 subjects) and Group 3 were relatives of patients receiving rAAVrh74 as part of a gene transfer trial (57 subjects). Enzyme-linked immunosorbent assay (ELISA)-based detection was used to identify anti-AAVrh74 total antibodies. Titers of 1:50 and 1:400 were reported, considering the range of titers used for enrollment in different trials. We found that parents of patients receiving gene transfer had a 3-fold greater risk of AAVrh74 seropositivity at 1:50 compared to the control group: 33.3% AAVrh74 positive (19/57 subjects) vs 13% negative (3/23 subjects), with a relative risk of 2.6%. Additionally, we observed that there were no statistically significant differences between two hospital personnel cohorts, non-exposed (Group 1) and exposed (Group 2), in terms of antibody positivity to AAVrh74. Finally, antibody titers at 1:400 were not different between Groups 1,2, or 3. These preliminary results serve as a caution to family members caring for children undergoing AAV gene transfer, warning that viral shedding following gene transfer can have an effect on the antibody titers. Prospective studies are on the way, with greater sample size, inclusive of pre- and post-treatment testing, and with the objective of establishing both the antibodies cut-off titers and the risk for acquiring immunity that could preclude gene transfer. The increasing number of gene therapy studies and exclusion of candidates from clinical trials highlights the potential importance of pre-existing antibodies targeting viral capsid. Viral antibodies block transduction and preclude expression of the transferred gene. Provoked immune response could also be a threat to safety. Testing patients for pre-existing antibodies, either neutralizing (Nabs) or total/binding (TAbs/BAbs), prior to gene transfer is a critical step in the initiation of a clinical trial. Previous studies assessed the seroprevalence of antibodies against different AAV subtypes in the general population and in patients receiving gene transfer. Our gene therapy studies for muscular dystrophy (DMD, LGMD) have currently shown promise for efficacy and safety, but we don't know if vector shedding post gene delivery affects the antibodies titer in family members of trial participants. This is particularly relevant for siblings who might become possible next gene therapy candidates. This pilot study included 115 subjects divided in three separate cohorts. Group 1 consisted of hospital personnel without known prior work exposure to rAAVrh74 (control group, 23 subjects). Group 2 were hospital-based personnel with known work exposure to rAAVrh74 (through pre-clinical and clinical studies, or direct contact with patient's specimen, 35 subjects) and Group 3 were relatives of patients receiving rAAVrh74 as part of a gene transfer trial (57 subjects). Enzyme-linked immunosorbent assay (ELISA)-based detection was used to identify anti-AAVrh74 total antibodies. Titers of 1:50 and 1:400 were reported, considering the range of titers used for enrollment in different trials. We found that parents of patients receiving gene transfer had a 3-fold greater risk of AAVrh74 seropositivity at 1:50 compared to the control group: 33.3% AAVrh74 positive (19/57 subjects) vs 13% negative (3/23 subjects), with a relative risk of 2.6%. Additionally, we observed that there were no statistically significant differences between two hospital personnel cohorts, non-exposed (Group 1) and exposed (Group 2), in terms of antibody positivity to AAVrh74. Finally, antibody titers at 1:400 were not different between Groups 1,2, or 3. These preliminary results serve as a caution to family members caring for children undergoing AAV gene transfer, warning that viral shedding following gene transfer can have an effect on the antibody titers. Prospective studies are on the way, with greater sample size, inclusive of pre- and post-treatment testing, and with the objective of establishing both the antibodies cut-off titers and the risk for acquiring immunity that could preclude gene transfer." @default.
• W4387310037 created "2023-10-04" @default.
• W4387310037 creator A5003380664 @default.
• W4387310037 creator A5016629548 @default.
• W4387310037 creator A5028919826 @default.
• W4387310037 creator A5047809221 @default.
• W4387310037 creator A5052534937 @default.
• W4387310037 creator A5064903338 @default.
• W4387310037 date "2023-10-01" @default.
• W4387310037 modified "2023-10-05" @default.
• W4387310037 title "P56 Preliminary study of anti-AAVrh74 seroprevalence following gene transfer" @default.
• W4387310037 doi "https://doi.org/10.1016/j.nmd.2023.07.037" @default.
• W4387310037 hasPublicationYear "2023" @default.
• W4387310037 type Work @default.
• W4387310037 citedByCount "0" @default.
• W4387310037 crossrefType "journal-article" @default.
• W4387310037 hasAuthorship W4387310037A5003380664 @default.
• W4387310037 hasAuthorship W4387310037A5016629548 @default.
• W4387310037 hasAuthorship W4387310037A5028919826 @default.
• W4387310037 hasAuthorship W4387310037A5047809221 @default.
• W4387310037 hasAuthorship W4387310037A5052534937 @default.
• W4387310037 hasAuthorship W4387310037A5064903338 @default.
• W4387310037 hasBestOaLocation W43873100371 @default.
• W4387310037 hasConcept C104317684 @default.
• W4387310037 hasConcept C111599444 @default.
• W4387310037 hasConcept C126322002 @default.
• W4387310037 hasConcept C159047783 @default.
• W4387310037 hasConcept C159654299 @default.
• W4387310037 hasConcept C203014093 @default.
• W4387310037 hasConcept C22889606 @default.
• W4387310037 hasConcept C2778494684 @default.
• W4387310037 hasConcept C2908647359 @default.
• W4387310037 hasConcept C32611913 @default.
• W4387310037 hasConcept C45189115 @default.
• W4387310037 hasConcept C535046627 @default.
• W4387310037 hasConcept C54355233 @default.
• W4387310037 hasConcept C71924100 @default.
• W4387310037 hasConcept C86803240 @default.
• W4387310037 hasConcept C99454951 @default.
• W4387310037 hasConceptScore W4387310037C104317684 @default.
• W4387310037 hasConceptScore W4387310037C111599444 @default.
• W4387310037 hasConceptScore W4387310037C126322002 @default.
• W4387310037 hasConceptScore W4387310037C159047783 @default.
• W4387310037 hasConceptScore W4387310037C159654299 @default.
• W4387310037 hasConceptScore W4387310037C203014093 @default.
• W4387310037 hasConceptScore W4387310037C22889606 @default.
• W4387310037 hasConceptScore W4387310037C2778494684 @default.
• W4387310037 hasConceptScore W4387310037C2908647359 @default.
• W4387310037 hasConceptScore W4387310037C32611913 @default.
• W4387310037 hasConceptScore W4387310037C45189115 @default.
• W4387310037 hasConceptScore W4387310037C535046627 @default.
• W4387310037 hasConceptScore W4387310037C54355233 @default.
• W4387310037 hasConceptScore W4387310037C71924100 @default.
• W4387310037 hasConceptScore W4387310037C86803240 @default.
• W4387310037 hasConceptScore W4387310037C99454951 @default.
• W4387310037 hasLocation W43873100371 @default.
• W4387310037 hasOpenAccess W4387310037 @default.
• W4387310037 hasPrimaryLocation W43873100371 @default.
• W4387310037 hasRelatedWork W1984647379 @default.
• W4387310037 hasRelatedWork W2332869960 @default.
• W4387310037 hasRelatedWork W2357994263 @default.
• W4387310037 hasRelatedWork W2365431450 @default.
• W4387310037 hasRelatedWork W2381957667 @default.
• W4387310037 hasRelatedWork W2381991529 @default.
• W4387310037 hasRelatedWork W2384171498 @default.
• W4387310037 hasRelatedWork W2414181163 @default.
• W4387310037 hasRelatedWork W3000660023 @default.
• W4387310037 hasRelatedWork W4386787256 @default.
• W4387310037 hasVolume "33" @default.
• W4387310037 isParatext "false" @default.
• W4387310037 isRetracted "false" @default.
• W4387310037 workType "article" @default.